Premium
In vivo imaging of the neutron capture therapy agent BSH in mice using 10 B MRI
Author(s) -
Bendel Peter,
Koudinova Natalia,
Salomon Yoram
Publication year - 2001
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.1154
Subject(s) - in vivo , nuclear medicine , neutron capture , nuclear magnetic resonance , boron , chemistry , radiochemistry , neutron temperature , nuclear magnetic resonance spectroscopy , tail vein , radiation therapy , gadolinium , melanoma , neutron , medicine , radiology , cancer research , physics , microbiology and biotechnology , organic chemistry , quantum mechanics , biology
Boron neutron capture therapy (BNCT) is an experimental cancer treatment modality requiring the targeting of 10 B‐enriched compounds to the tumor, which is then irradiated by low‐energy neutrons. One of the boron‐containing compounds used for this purpose is the mercaptoborane Na 2 B 12 H 11 SH (BSH). The first in vivo MR images of 10 B‐enriched BSH are presented here. BSH, injected into the tail vein of mice with implanted M2R melanoma xenografts, was imaged using 3D gradient echo 10 B MRI. 10 B NMR spectroscopy, localized mainly to the tumor by virtue of the use of a small surface coil, was applied to measure the T 1 (2.9 ± 0.3 ms) and T 2 (1.75 ± 0.25 ms) values of the 10 B signal. The MRI experiments detected levels of about 20 ppm (μg boron / g tissue) at 6 × 6 × 6 mm spatial resolution in a total scan time of 16 min. Magn Reson Med 46:13–17, 2001. © 2001 Wiley‐Liss, Inc.